Ultragenyx Pharmaceutical (RARE) Trading 6.7% Higher
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)’s share price traded up 6.7% during mid-day trading on Wednesday . The stock traded as high as $47.87 and last traded at $47.63. 503,289 shares were traded during trading, a decline of 25% from the average session volume of 675,042 shares. The stock had previously closed at $44.65.
Several equities analysts have recently issued reports on the company. BidaskClub cut Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, February 9th. Zacks Investment Research cut Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Raymond James Financial reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Friday, December 15th. Canaccord Genuity set a $80.00 price target on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Thursday, November 16th. Finally, Barclays lifted their price target on Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 5th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $72.06.
The company has a market capitalization of $2,080.28, a price-to-earnings ratio of -6.83 and a beta of 1.89.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.